drugset / Trial / NCT05009862
The Impact of Factor Xa Inhibition on Thrombosis, Platelet Activation, and Endothelial Function in Peripheral Artery Disease
Phase 4
Completed
60 enrolled
Vanderbilt University Medical Center
National Heart, Lung, and Blood Institute (NHLBI) · collab
RandomizedCrossoverQuadruple-blindPrevention
Summary
The purpose of this study is to understand how the drug rivaroxaban improves symptoms associated with peripheral artery disease.
Timeline
- Start
- 2022-04-19
- Primary completion
- 2025-07-01
- Completion
- 2025-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rivaroxaban | Other / unclassified | 2.5 mg | Oral |
| Background | Aspirin | Small molecule | 81 mg | — |